To assess the Pharmacokinetics and pharmacodynamics of single doses of ASP1517 in renal anemia patients on hemodialysis. Safety and tolerability will be also evaluated in these patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
12
oral
Unnamed facility
Chūbu, Japan
ASP1517 concentrations in plasma
Time frame: For 96 hours after dosing
ASP1517 concentrations in dialysate
Time frame: For 6 hours after dosing
Plasma EPO level
Time frame: Pre dosing and for 24 hours after dosing
Safety assessed by Adverse Event, vital signs standard 12-lead ECG or lab tests
Time frame: For 96 hours after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.